Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 302

Similar articles for PubMed (Select 21936620)

1.

18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.

Walter F, Federman N, Apichairuk W, Nelson S, Phelps ME, Allen-Auerbach M, Walter MA, Czernin J.

Pediatr Hematol Oncol. 2011 Oct;28(7):579-87. doi: 10.3109/08880018.2011.602180.

PMID:
21936620
2.

Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients.

Rakheja R, Makis W, Skamene S, Nahal A, Brimo F, Azoulay L, Assayag J, Turcotte R, Hickeson M.

AJR Am J Roentgenol. 2012 Jun;198(6):1409-16. doi: 10.2214/AJR.11.7560.

PMID:
22623556
3.

Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.

Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH.

J Nucl Med. 2005 Jun;46(6):945-52.

4.

The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.

Shin DS, Shon OJ, Han DS, Choi JH, Chun KA, Cho IH.

Ann Nucl Med. 2008 Aug;22(7):603-9. doi: 10.1007/s12149-008-0151-2. Epub 2008 Aug 29.

PMID:
18756363
5.
6.

Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography.

Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Hasegawa T.

Eur J Nucl Med Mol Imaging. 2006 Jun;33(6):683-91. Epub 2006 Feb 28.

PMID:
16506050
7.

The role of 18F-FDG PET/CT in the metabolic characterization of lung nodules in pediatric patients with bone sarcoma.

Cistaro A, Lopci E, Gastaldo L, Fania P, Brach Del Prever A, Fagioli F.

Pediatr Blood Cancer. 2012 Dec 15;59(7):1206-10. doi: 10.1002/pbc.24242. Epub 2012 Jun 28.

PMID:
22745027
8.

Uptake in supraclavicular area fat ("USA-Fat"): description on 18F-FDG PET/CT.

Cohade C, Osman M, Pannu HK, Wahl RL.

J Nucl Med. 2003 Feb;44(2):170-6.

9.

18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.

Zhao Z, Yoshida Y, Kurokawa T, Kiyono Y, Mori T, Okazawa H.

J Nucl Med. 2013 Apr;54(4):499-506. doi: 10.2967/jnumed.112.113472. Epub 2013 Mar 7.

10.

Overexpression of hexokinase-2 in giant cell tumor of bone is associated with false positive in bone tumor on FDG-PET/CT.

Hoshi M, Takada J, Oebisu N, Hata K, Ieguchi M, Nakamura H.

Arch Orthop Trauma Surg. 2012 Nov;132(11):1561-8. doi: 10.1007/s00402-012-1588-2. Epub 2012 Jul 24.

PMID:
22825642
11.

Interobserver variability among measurements of the maximum and mean standardized uptake values on (18)F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors.

Huang YE, Chen CF, Huang YJ, Konda SD, Appelbaum DE, Pu Y.

Acta Radiol. 2010 Sep;51(7):782-8. doi: 10.3109/02841851.2010.497772.

PMID:
20707663
12.

Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients?

Walter F, Czernin J, Hall T, Allen-Auerbach M, Walter MA, Dunkelmann S, Federman N.

J Pediatr Hematol Oncol. 2012 Mar;34(2):131-6. doi: 10.1097/MPH.0b013e3182282825.

PMID:
22134608
13.

18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas.

Been LB, Suurmeijer AJ, Elsinga PH, Jager PL, van Ginkel RJ, Hoekstra HJ.

J Nucl Med. 2007 Mar;48(3):367-72.

14.

Quantitative, dynamic 18F-FDG-PET for the evaluation of soft tissue sarcomas: relation to differential diagnosis, tumor grading and prediction of prognosis.

Okazumi S, Dimitrakopoulou-Strauss A, Schwarzbach MH, Strauss LG.

Hell J Nucl Med. 2009 Sep-Dec;12(3):223-8.

PMID:
19936332
15.

[18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation.

Buchmann I, Vogg AT, Glatting G, Schultheiss S, Möller P, Leithäuser F, Schulte M, Gfrörer W, Kotzerke J, Reske SN.

Cancer Biother Radiopharm. 2003 Jun;18(3):327-37.

PMID:
12954120
16.

Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT.

Sauter AW, Winterstein S, Spira D, Hetzel J, Schulze M, Mueller M, Pfannenberg C, Claussen CD, Klotz E, Hann von Weyhern C, Horger MS.

J Nucl Med. 2012 Apr;53(4):521-9. doi: 10.2967/jnumed.111.097865. Epub 2012 Mar 13.

17.

(18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.

Al-Ibraheem A, Buck AK, Benz MR, Rudert M, Beer AJ, Mansour A, Pomykala KL, Haller B, Juenger H, Scheidhauer K, Schwaiger M, Herrmann K.

Cancer. 2013 Mar 15;119(6):1227-34. doi: 10.1002/cncr.27866. Epub 2012 Dec 11.

18.

Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas.

Lee SW, Nam SY, Im KC, Kim JS, Choi EK, Ahn SD, Park SH, Kim SY, Lee BJ, Kim JH.

Radiother Oncol. 2008 May;87(2):211-6. doi: 10.1016/j.radonc.2008.01.009. Epub 2008 Jan 30.

PMID:
18237806
19.

Dual time point 2-[18F]fluoro-2'-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis.

Sahlmann CO, Siefker U, Lehmann K, Meller J.

Nucl Med Commun. 2004 Aug;25(8):819-23.

PMID:
15266177
20.

Thyroid incidentaloma detected by fluorodeoxyglucose positron emission tomography/computed tomography: practical management algorithm.

Nilsson IL, Arnberg F, Zedenius J, Sundin A.

World J Surg. 2011 Dec;35(12):2691-7. doi: 10.1007/s00268-011-1291-4.

PMID:
21989645
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk